Close Menu

cell-free DNA

Natera plans to launch its clinical oncology and transplantation tests next year and is hopeful that guidelines endorsing NIPT for average-risk pregnancies are imminent.

The molecular diagnostics firm grew year-over-year testing volumes by 28 percent to 167,172.

The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.

DiaCarta scientists will partner with the University of Florida Health Cancer Center to analyze blood samples from up to 500 cancer patients undergoing radiotherapy.

The Stanford spinout has launched an infectious disease test that sequences cell-free pathogen DNA to diagnose sepsis in immunocompromised patients.

The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.

A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.

The firm is working on harnessing its ability to assess fetal fraction to develop new methods to predict fetal aneuploidy risks and pregnancy complications.

The firm recognized $63.1 million in revenues and processed 162,807 tests in the second quarter 2018.

Protein platforms revenues grew 21 percent, while biotechnology revenues were up 18 percent, and diagnostic revenues increased 2 percent.

Pages